The impact of functional imaging on radiation medicine

Radiation Oncology

Volumn 3, Issue 1, 2008, Pages

  Sharma, Nidhi ^a   Neumann, Donald ^a   Macklis, Roger ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; DIAGNOSTIC IMAGING; ECONOMICS; HUMAN; INSTRUMENTATION; MEDICARE; METHODOLOGY; NEOPLASM; NUCLEAR MEDICINE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; UNITED STATES;

DIAGNOSTIC IMAGING; HUMANS; MEDICARE; NEOPLASM STAGING; NEOPLASMS; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIATION ONCOLOGY; RADIOPHARMACEUTICALS; UNITED STATES;

EID: 53149144323     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-3-25     Document Type: Review

References (87)

1. Adler L Faulhaber P Schnur K Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET Radiology 1997, 203:323-27. 9114082
2. Avril N Dose J Janicke Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose J Natl Cancer Inst 1996, 88:1204-9. 10.1093/jnci/88.17.1204 8780629
3. Adams S Baum RP Stuckensen T Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MR, US) in lymph node staging of head and neck cancer Eur J Nucl Med 1998, 25(9):1255-1260. 10.1007/ s002590050293 9724374
4. Stokkel MP Broek FW vanRijk PP The role of FDG PET in the clinical management of head and neck cancer Oral Oncol 1998, 34:466-71. 10.1016/ S1368-8375(98)00050-5 9930356
5. Boykin KN Zibari GB Lilien DL The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver Am Surg 1999, 65:1183-5. 10597072
6. Fong Y Saldinger PF Akhurst T Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases Am J Surg 1999, 178:282-7. 10.1016/ S0002-9610(99)00187-7 10587184
7. Gambhir SS Czernin J Schwimmer J Silverman DH Coleman RE Phelps ME A tabulated summary of the FDG-PET literature J Nucl Med 2001, 42(5 Suppl):1S-93S. 11483694
8. Maurer AH Urbain JLC Malmud LS Grainger & Allison's Diagnostic Radiology: A textbook of Medical Imaging London: Churchill 4.
9. de Wit M Bumann D Beyer W Whole-body positron emissiontomography (PET) for diagnosis of residual mass in patients withlymphoma Ann Oncol Livingstone Inc 1997, 8:57-60. 2001 10.1023/A:1008253917337 9187431
10. Wiedmann E Baican B Hertel A Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease Leuk Lymphoma 1999, 34:545-51. 10492078
11. Zinzani PL Magagnoli M Chierichetti F The role of positron emission tomography (PET) in the management of lymphoma patients Ann Oncol 1999, 10:1181-84. 10.1023/A:1008327127033 10586334
12. Castellucci P Nanni C Farsad M Alinari L Zinzani P Stefoni V Battista G Valentini D Pettinato C Marengo M Boschi S Canini R Baccarani M Monetti N Franchi R Rampin L Fanti S Rubello D Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: Prevalence and scan interpretation Nucl Med Commun 2005, 26(8):689-94. 10.1097/ 01.mnm.0000171781.11027.bb 16000986
13. Romer W Hanauske AR Ziegler S Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose Blood 1998, 91:4464-71. 9616140
14. Wahl RL Zasadny K Helvie M Metabolic monitoring of breast cancer chemohormonotherapy using positron emession tomography: Initial evaluation J Clin Oncol 1993, 11:2101-2111. 8229124
15. Bassa P Kim EE Inoue T Evaluation of preoperative chemotheraphy using PET with fluorine-18-fluorode-oxyglucose in breast cancer J Nucl Med 1996, 37:931-8. 8683314
16. Herrmann K Krause B Wester H Change of tumor cell proliferation during R-CHOP chemotherapy of diffuse large B-cell lymphoma (DLBCL) measured by 18FLT-PET Presented at: Society of Nuclear Medicine 53rd Annual Meeting; June 3-7, 2006; San Diego.
17. Kahn ST Flowers C Lechowicz MJ Hollenbach K Johnstone PA Value of PET restaging after CT for non Hodgkin's lymphoma: Implications for consolidation Radiotherapy Int J Radiat Oncol Biol Phys 2006, 66(4):961-5. 17145526
18. Bentzen SM Theragnostic imaging for radiation oncology: Dose painting by numbers Lancet Oncol 2005, 6:112-17. 10.1016/S1470-2045(05)01737-7 15683820
19. Champman JD Bradley JD Eary JF Haubner R Larson SM Michalski JM Okunieff PG Strauss HW Ung YC Welch MJ Molecular (functional) imaging for radiotherapy applications: An RTOG symposium Int J Radiat Oncol Biol Phys 2003, 55(2):294-301. 12527041
20. Cheson BD Pfistner B Juweid ME Gascoyne RD Specht L Horning SJ Coiffier B Fisher RI Hagenbeek A Zucca E Rosen ST Stroobants S Lister TA Hoppe RT Dreyling M Tobinai K Vose JM Connors JM Federico M Diehl V The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma J Clin Oncol 25(5):579-86. 2007 Feb 10 10.1200/JCO.2006.09.2403 17242396
21. Juweid ME Stroobants S Hoekstra OS Mottaghy FM Dietlein M Guermazi A Wiseman GA Kostakoglu L Scheidhauer K Buck A Naumann R Spaepen K Hicks RJ Weber WA Reske SN Schwaiger M Schwartz LH Zijlstra JM Siegel BA Cheson BD Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25(5):571-8. 2007 Feb 10 10.1200/JCO.2006.08.2305 17242397
22. Zanzonico P PET-based biological imaging for radiation therapy treatment planning Crit Rev Eukaryot Gene Expr 2006, 16(1):61-101. 16584383
23. Schwartz DL Ford E Rajendran J Yueh B Coltrera MD Virgin J Anzai Y Haynor D Lewellyn B Mattes D Meyer J Phillips M Leblanc M Kinahan P Krohn K Eary J Laramore GE FDG-PET/CT imaging for pre radiotherapy staging of head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 61(1):129-36. 2005 Jan 1 15629603
24. Grosu AL Weber WA Astner ST Adam M Krause BJ Schwaiger M Molls M Nieder C 11C-methionine PET improves the target volume delineation of meningiomas treated with stereo tactic fractionated radiotherapy Int J Radiat Oncol Biol Phys 66(2):339-44. 2006 Oct 1 16765533
25. Kitagawa Y Sano K Nishizawa S Nakamura M Ogasawara T Sadato N Yonekura FDG-PET for prediction of tumor aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer Eur J Nucl Med Mol Imaging 2003, 30(1):63-71. Epub 2002 Oct 26 10.1007/ s00259-002-0978-z 12483411
26. Stuckensen T Kovacs AF Adams S Baum RP Staging of theneck in patients with oral cavity squamous cell carcinomas: A prospective comparison of PET, ultrasound, CT and MRI J Craniomaxillofac Surg 2000, 28:319-24. 11465137
27. Benchaou M Lehmann W Slosman DO Becker M Lemoine R Rufenatch D Donath A The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer Acta Otolaryngol (Stockh) 1996, 116:332-5. 10.3109/ 00016489609137852 8725543
28. Kau RJ Alexiou C Laubenbacher C Werner M Schwaiger M Arnold W Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F18 in a routine clinical setting Arch Otolaryngol Head Neck Surg 1999, 125(12):1322-8. 10604409
29. Douglas JG Stelzar KJ Mankoff DA Tralins KS Krohn KA Muzi M Silbergeld DL Rostomily RC Scharnhorst J Spence AM [F-18]-fluorodeoxyglucose positron emission tomography fortargeting radiation dose escalation for patients with glioblastomamultiforme: Clinical outcomes and patterns of failure Int J Radiat Oncol Biol Phys 64(3):886-91. 2006 Mar 1, Epub 2005 Oct 19 16242251
30. Schwartz DL Ford EC Rajendran J Yueh B Coltrera MD Virgin J Anzai Y Haynor D Lewellyn B Mattes D Meyer J Phillips M Leblanc M Kinahan P Krohn K Eary J Laramore GE FDG-PET/CT-guided intensity modulated head and neck radiotherapy: A pilot investigation Head Neck 2005, 27(6):478-87. 10.1002/hed.20177 15772953
31. Lowe VJ Boyd JH Dunphy FR Kim H Dunleavy T Collins BT Martin D Stack BC Jr Hollenbeak C Fletcher JW Surveillance for recurrent head and neck cancer using positron emission tomography J Clin Oncol 2000, 18:651-8. 10653881
32. Kunkel M Grotz KA Forster GJ Wahlmann U Benz P Kutzner J Rippins G Wagner W Therapy monitoring with 2-(18F)-FDG positron emission tomography after neoadjuvant radiation treatment of mouth carcinoma Strahlenther Onkol 2001, 177:145-52. 10.1007/PL00002395 11285772
33. Nishioka T Shiga T Shirato H Tsukamoto E Tsuchiya K Kato T Ohomori K Yamazaki A Aoyama H Hashimoto S Chang TC Miyasaka K Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas J Radiat Oncol Biol Phys 2002, 53:1051-7. 10.1016/S0360-3016(02)02854-7
34. Heron DE Smith RP Andrade RS Advances in image-guided radiation therapy - the role of PET-CT Med Dosim Spring 2006, 31(1):3-11. 10.1016/ j.meddos.2005.12.006 16551524
35. Greven KM Williams DW Keyes JW et al. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? Cancer J Sci Am 1997, 3:353-7. 9403048
36. Farber LA Benard F Machtay M et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18 F-fluoro-2-deoxy-D-glucose positron emission tomography Laryngoscope 1999, 109:970-5. 10.1097/00005537-199906000-00024 10369292
37. Lowe VJ Dunphy FR Varvares M et al. Evaluation of chemotherapy response with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography Head Neck 1997, 19:666-674. 10.1002/ (SICI)1097-0347(199712)19:8<666::AID-HED4>3.0.CO;2-3 9406745
38. Kau RJ Alexiou C Laubenbacher C Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with [F-18] fluorodeoxyglucose in routine clinical setting Arch Otolaryngol Head Neck Surg 1999, 125:1322-8. 10604409
39. Wolfort RM Li BD Johnson LW Turnage RH Lilien D Ampil F Burton G Chu QD The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer World J Surg 2006, 30(8):1422-7. 10.1007/ s00268-005-0207-6 16715451
40. Weir L Worsley D Bernstein V The value of FDG positron emission tomography in the management of patients with breast cancer Breast J 2005, 11(3):204-9. 10.1111/j.1075-122X.2005.21625.x 15871707
41. Kumar R Alavi A Fluorodeoxyglucose-PET in the management of breast cancer Radiol Clin North Am 2004, 42(6):1113-22. 10.1016/ j.rcl.2004.08.005 15488561
42. Port ER Yeung H Gonen M Liberman L Caravelli J Borgen P Larson S 18F-2-fluoro-2-deoxy-D-glucose positron emissiontomography scanning affects surgical management in selected patientswith high-risk, operable breast carcinoma Ann Surg Oncol 2006, 13(5):677-84. Epub 2006 Mar 16 10.1245/ASO.2006.03.035 16538409
43. Marshall C Mustafa S Wheatley DC Eremin JE El-Sheemy M Jibril JA Eremin O Griffiths PA A comparison of 18F-FDG gamma camera PET, mammography and ultrasonography in demonstrating primary disease in locally advanced breast cancer Nucl Med Commun 2004, 25(7):721-5. 10.1097/ 01.mnm.0000130239.76326.ca 15208500
44. Kawada K Murakami K Sato T Kojima Y Ebi H Mukai H Tahara M Shimokata K Minami H Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in patients with advanced tumors Jpn J Clin Oncol 2007, 37(1):44-8. 10.1093/jjco/hyl116 17060407
45. Radan L Ben-Haim S Bar-Shalom R Guralnik L Israel O The role of FDG PET/ CT in suspected recurrence of breast cancer Cancer 107(11):2545-51. 2006 Dec 1 10.1002/cncr.22292 17063499
46. Obedian E Haffty BG Internal mammary nodal irradiation in conservatively-managed breast cancer patients: Is there a benefit? Int J Radiat Oncol Biol Phys 44(5):997-1003. 1999 Jul 15 10421532
47. Weber WA Dietlein M Hellwig D Kirsch CM Schicha H Schwaiger M PET with (18) F-fluorodeoxyglucose for staging of non-small cell lung cancer Nuklearmedizin 2003, 42:135-44. 12937692
48. van Tinteren H Hoekstra OS Smit EF Bergh van den JH Schreurs AJ Stallaert RA van Velthoven PC Comans EF Diepenhorst FW Verboom P van Mourik JC Postmus PE Borres M Teule GJ Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicenter randomized trial Lancet 2002, 359(9315):1388-93. 10.1016/S0140-6736(02)08352-6 11978336
49. Esteves FP Schuster DM Halkar RK Gastrointestinal tract malignancies and positron emission tomography: An overview Semin Nucl Med 2006, 36(2):169-81. 10.1053/j.semnuclmed.2005.12.002 16517238
50. Sonmezoglu K The use of FDG-PET scanning in lung cancer Tuberk Toraks 2005, 53(1):95-114. Review Turkish 15765294
51. Schrevens L Lorent N Dooms C Vansteenkiste J The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer Oncologist 2004, 9(6):633-43. Review 10.1634/theoncologist.9-6-633 15561807
52. Hauber HP Bohuslavizki KH Lund CH Fritscher-Ravens A Meyer A Pforte A Positron Emission Tomography in the staging of Small cell lung cancer: A preliminary study Chest 2001, 119(3):950-4. 10.1378/chest.119.3.950 11243980
53. Craig MD Rogers JS Gupta N Evaluation of PET scan in small cell lung cancer.2004 ASCO Annual meeting proceedings J Clin Oncol 2004, 22:7214.
54. Steinert HC Santos Dellea MM Burger C Stahel R Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging Lung Cancer 2005, 49(Suppl 1):S33-5. 10.1016/ j.lungcan.2005.03.006 15950798
55. Erasmus JJ McAdams HP Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography AJR Am J Roentgenol 1997, 168:1357-1360. 9129444
56. Weber WA Petersen V Schmidt B Tyndale-Hines L Link T Peschel C Schwaiger M Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 2003, 21:2651-7. 10.1200/JCO.2003.12.004 12860940
57. Flamen P Lerut A Van Cutsem E De Wever W Peeters M Stroobants S Dupont P Bormans G Hiele M De Leyn P Van Raemdonck D Coosemans W Ectors N Haustermans K Mortelmans L Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J Clin Oncol 2000, 18(18):3202-10. 10986052
58. Lim JS Yun MJ Kim MJ Hyung WJ Park MS Choi JY Kim TS Lee JD Noh SH Kim KW CT and PET in stomach cancer: Preoperative staging and monitoring of response to therapy Radiographics 2006, 26(1):143-56. Review 10.1148/ rg.261055078 16418249
59. Heinrich S Goerres GW Schaefer M Sagmeister M Bauerfeind P Pestalozzi BC Hany TF von Schulthess GK Clavien PA Positron emission tomography/ computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness Ann Surg 2005, 242(2):235-43. 1357729 16041214 10.1097/01.sla.0000172095.97787.84
60. Turlakow A Yeung HW Salmon AS Macapinlac HA Larson SM Peritoneal carcinomatosis: Role of (18) F-FDG PET J Nucl Med 2003, 44(9):1407-12. 12960184
61. Herholz K Holzer T Bauer B Schroder R Voges J Ernestus RI Mendoza G Weber-Luxenburger G Lottgen J Thiel A Wienhard K Heiss WD 11C-methionine PET for differential diagnosis of low grade gliomas Neurology 1998, 50:1316-22. 9595980
62. DiChiro G Positron emission tomography using F-18 fluorodeoxyglucose in brain tumors- a powerful diagnostic and prognostic tool Invest Radiol 1986, 22:360-71.
63. Alavi JB Alavi A Chawluk J Kushner M Powe J Hickey W Reivich M Positron emission tomography in patients with glioma. A predictor of prognosis Cancer 1988, 62:1074-8. 10.1002/ 1097-0142(19880915)62:6<1074::AID-CNCR2820620609>3.0.CO;2-H 3261622
64. Solberg TD Agazaryan N Goss BW Dahlbom M Lee SP A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity modulated radiosurgery and radiotherapy J Neurosurg 2004, 101:381-9. 15537193
65. Grosu AL Lachner R Wiedenmann N Stark S Thamm R Kneschaurek P Schwaiger M Molls M Weber WA Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine- PET data for stereotactic radiotherapy using a LINAC: First clinical experience Int J Radiat Oncol Biol Phys 2003, 56:1450-63. 10.1016/S0360-3016(03)00279-7 12873691
66. Sweeney RA Bale RJ Moncayo R Seydl K Trieb T Eisner W Burtscher J Donnemiller E Stockhammer G Lukas P Multimodality cranial image fusion using external markers applied via vacuum mouthpiece and a case report Strahlenther Onkol 2003, 179:254-60. 10.1007/s00066-003-1031-2 12707715
67. Grigsby PW Siegel BA Dehdashti F Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J Clin Oncol 2001, 19(17):3745-9. 11533097
68. Havrilesky LJ Wong TZ Secord AA Berchuck A Clarke-Pearson The role of PET scanning in the detection of recurrent cervical cancer Gynecol Oncol 2003, 90(1):186-90. 10.1016/S0090-8258(03)00256-7 12821362
69. Reinhardt MJ Ehritt-Braun C Vogelgesang D Ihling C Hogerle S Mix M Moser E Krause TM Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET Radiology 2001, 218(3):776-82. 11230656
70. Dehdashti F Grigsby PW Mintun MA Lewis JS Siegel BA Welch MJ Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response - a preliminary report Int J Radiat Oncol Biol Phys 2003, 55(5):1233-8. 12654432
71. Esthappan J Mutic S Malyapa RS Grigsby PW Zoberi I Dehdashti F Miller TR Bosch WR Low DA Treatment planning guidelines regarding the use of CT/ PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes Int J Radiat Oncol Biol Phys 58(4):1289-97. 2004 Mar 15 15001274
72. Yen TC Lai CH Positron emission tomography in gynecologic cancer Semin Nucl Med 2006, 36(1):93-104. 10.1053/j.semnuclmed.2005.08.004 16356798
73. Bristow RE Simpkins F Pannu HK Fishman EK Montz FJ Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer Gynaecol Oncolol 2002, 85(1):196-200. 10.1006/ gyno.2002.6611 11925145
74. Cohn DE Dehdashti F Gibb RK Mutch DG Rader JS Siegel BA Herzog TJ Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer Gynaecol Oncol 2002, 85(1):179-84. 10.1006/gyno.2002.6605 11925141
75. Moul JW Prostate specific antigen only progression of prostate cancer J Urol 2000, 163:1632-42. 10.1016/S0022-5347(05)67511-8 10799151
76. Effert PJ Bares R Handt S Wolff JM Bull U Jakse G Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose J Urol 1996, 155(3):994-8. 10.1016/ S0022-5347(01)66366-3 8583625
77. Hofer C Laubenbacher C Block T Breul J Hartung R Schwaiger M Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur Urol 1999, 36(1):31-5. 10.1159/000019923 10364652
78. Shreve PD Grossman HB Gross MD Wahl RL Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose Radiology 1996, 199(3):751-6. 8638000
79. Kumar R Zhuang H Alavi A PET in the management ofurologic malignancies Radiol Clin North Am 2004, 42(6):1141-53. Review 10.1016/ j.rcl.2004.08.007 15488563
80. Morris MJ Akhurst T Osman I Nunez R Macapinlac H Siedlecki K Verbel D Schwartz L Larson SM Scher HI Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 2002, 59(6):913-8. 10.1016/S0090-4295(02)01509-1 12031380
81. Mathews D Oz OK Positron emission tomography in prostate and renal cell carcinoma Curr Opin Urol 2002, 12(5):381-5. 10.1097/ 00042307-200209000-00003 12172424
82. Bybel B Brunken RC Shah SN Guiyun W Turbiner E Neumann DR PET and PET/CT imaging: What clinicians need to know? Cleve Clin J Med 2006, 73(12):1075-1087. 17190311
83. Juweid ME Stroobants S Hoekstra OS Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 2007, 25:571-8. 10.1200/JCO.2006.08.2305 17242397
84. Bradley J Thorstad WL Mutic S Impact of FDG-PET onradiation therapy volume delineation in non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2004, 59:78-86. 15093902
85. van Baardwijk A Baumert BG Bosmans G The currentstatus of FDG-PET in tumor volume definition in radiotherapy treatment planning Cancer Treat Rev 2006, 32:245-60. 10.1016/j.ctrv.2006.02.002 16563636
86. Hutchings M Loft A Hansen M Berthelsen AK Specht L Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma Eur J Haematol 2007, 78:206-12. 10.1111/ j.1600-0609.2006.00802.x 17253974
87. Girinsky T Maazen van der R Specht L et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines Radiother Oncol 2006, 79:270-7. 10.1016/j.radonc.2006.05.015 16797755